Showing all 2 results
-
Diacef
1,024.00৳Special precautions for useSpecial precautions for use in animals
This veterinary medicinal product selects resistant strains such as broad-spectrum beta-lactamase (BLAE) carrying bacteria that may pose a risk to human health if those strains are spread to humans, e.g. through food. For this reason, this veterinary medicinal product should be reserved for the treatment of clinical conditions that have responded poorly or that are expected to respond poorly (refers to very acute cases that require treatment without a bacteriological diagnosis) to first-line treatment. When using the veterinary medicinal product, official, national and regional antimicrobial recommendations should be taken into account. Greater use than intended or use that deviates from the instructions provided in the label may increase the prevalence of these resistances. Whenever possible, the use of this veterinary medicinal product should be based on susceptibility testing.
Do not use as prophylaxis in case of retained placenta.
This veterinary medicinal product is intended for the treatment of specific animals. Do not use for disease prevention or as part of herd health programs. The treatment of groups of animals should be strictly limited to active outbreaks of disease in accordance with the approved conditions of use.
Specific precautions to be taken by the person administering the veterinary medicinal product to animals
Penicillins and cephalosporins may cause hypersensitivity (allergy) after injection, inhalation, ingestion or contact with the skin. Hypersensitivity to penicillins can lead to cross-reactions with cephalosporins and vice versa. Allergic reactions to these substances can sometimes be serious.
Do not handle the veterinary medicinal product in case of known hypersensitivity or if you have been instructed not to work with such preparations.
Handle the veterinary medicinal product with great caution to avoid exposure, taking all recommended precautions.
In case of accidental self-injection or if you develop symptoms after exposure such as skin rashes, consult a doctor immediately and show the leaflet or label. Swelling of the face, lips, or eyes, or shortness of breath are more serious symptoms that require urgent medical attention.
Wash hands after use. -
Megluvet
1,024.00৳CLINICAL INFORMATION3.1 Target speciesCattle and horses3.2 Indications for use, for each of the target speciesBovine: Complementary therapy in the treatment of bovine respiratory diseases, endotoxemia and acute mastitis.Relief of acute inflammation and pain associated with musculoskeletal disorders. Reduction of postoperative pain associated with dehorning in calves less than 9 weeks of age.Horses: Relief of acute inflammation and pain associated with musculoskeletal disorders. Relief of visceral pain associated with colic.Concomitant therapy of endotoxemia due to or as a result of post-surgical or medical conditions or diseases that result in alterations in blood circulation in the gastrointestinal tract.
Reduction of pyrexia.3.3 Contraindications– Do not use in animals suffering from heart, liver or kidney disease or in which there is a possibility of ulcers or gastrointestinal bleeding– Do not use in cases of hypersensitivity to the active substance or any of the excipients– Do not use if hematopoiesis or hemostasis are altered.– Do not use in case of colic caused by ileus and associated with dehydration.3.4 Special WarningsNone.3.5 Special Precautions for UseSpecial precautions for safe use in target speciesInject slowly as life-threatening shock symptoms may occur due to the propylene glycol content.NSAIDs are known to have the potential to delay labor through a tocolytic effect by inhibiting prostaglandins, which are important in signaling the onset of labor. The use of the veterinary medicinal product in the immediate postpartum period may interfere with uterine involution and expulsion of fetal membranes, leading to retained placenta.The veterinary medicinal product must be at a temperature similar to body temperature. At the onset of the first symptoms of shock, discontinue administration immediately and initiate treatment for shock, if necessary.
